Quarterly report pursuant to Section 13 or 15(d)

Segment, Geographical and Other Revenue Information (Tables)

v3.20.1
Segment, Geographical and Other Revenue Information (Tables)
3 Months Ended
Mar. 31, 2020
Segment Reporting [Abstract]  
Schedule of segment reporting
The following table provides financial information by our reportable business segments along with a reconciliation to consolidated loss before income taxes (in thousands):
Three months ended March 31, 2020 Three months ended March 31, 2019
Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total
Revenues:
Product revenue $ 5,100    $ —    $ 5,100    $ 7,988    $ —    $ 7,988   
Research and development revenue 5,774    3,796    9,570    2,099    5,496    7,595   
Total revenues 10,874    3,796    14,670    10,087    5,496    15,583   
Costs and operating expenses:
Cost of product revenue 2,541    —    2,541    4,391    —    4,391   
Research and development(1)
5,696    4,925    10,621    4,442    3,317    7,759   
Selling, general and administrative(1)
2,345    591    2,936    2,101    517    2,618   
Total segment costs and operating expenses 10,582    5,516    16,098    10,934    3,834    14,768   
Income (loss) from operations $ 292    $ (1,720)   (1,428)   $ (847)   $ 1,662    815   
Corporate costs (2)
(5,727)   (5,575)  
Depreciation and amortization (492)   (373)  
Loss before income taxes $ (7,647)   $ (5,133)  
(1) Research and development expenses and Selling, general and administrative expenses exclude depreciation and amortization of finance leases.
(2) Corporate costs include unallocated selling, general and administrative expense, interest income, and other income and expenses.

The following table provides stock-based compensation expense included in loss from operations (in thousands):
Three months ended March 31,
2020 2019
Performance Enzymes Novel Biotherapeutics Corporate cost Total Performance Enzymes Novel Biotherapeutics Corporate cost Total
Stock-based compensation $ 756    $ 241    $ 1,172    $ 2,169    $ 636    $ 141    $ 1,286    $ 2,063   
Schedule of customers that contributed 10% or more of total accounts receivable
Customers that each accounted for 10% or more of our total revenues were as follows:
Three Months Ended March 31,
2020 2019
Customer A 24  % 41  %
Customer B 19  % —  %
Customer C 15  % —  %
Customer D 11  % 35  %
Customers that each accounted for 10% or more of accounts receivable had balances as of the periods presented as follows:
Percentage of Accounts Receivables as of
March 31, 2020 December 31, 2019
Customer A 47  % 38  %
Customer D —  % 10  %
* Percentage was less than 10%
Schedule of revenues by geographical area
Geographic revenues are identified by the location of the customer and consist of the following (in thousands):
  Three Months Ended March 31,
2020 2019
Revenues
Americas $ 5,225    $ 2,838   
EMEA 5,971    7,726   
APAC 3,474    5,019   
Total revenues $ 14,670    $ 15,583   
Schedule of long-lived assets by geographical area
Identifiable long-lived assets by location was as follows (in thousands):
Long-lived assets March 31, 2020 December 31, 2019
United States    $ 6,647    $ 6,282   
Schedule of intangible assets and goodwill
Identifiable goodwill was as follows (in thousands):
March 31, 2020 December 31, 2019
Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total
Goodwill    $ 2,463    $ 778    $ 3,241    $ 2,463    $ 778    $ 3,241